Apolipoprotein Assessment
Apolipoproteins are the protein constituents of the lipoproteins that are the transporters of cholesterol and other important cell molecules. The Apolipoprotein Assessment consists of the Apolipoprotein A1 (an apoprotein of the High Density Lipoproteins-HDL) and Apolipoprotein B (major protein component of Low Density Lipoprotein-LDL). Apolipoproteins are produced in the liver and intestine. There are at least nine types of apolipoproteins including apo A-I, apo B, and apo E. Apolipoprotein A (apo A) is the major polypeptide component of HDL. Apo A has two major forms: apo A-I which constitutes 75% of the apo A in HDL, and apo A-II which constitutes the remainder of apo A of the total HDL protein. Low levels of apo A are associated with the increased risk of coronary artery disease (CAD).
Apo B is the major polypeptide component of LDL and makes up to 80% of the LDL protein. It exists in two forms: apo B-100 and apo B-48. Apo B-100 has an affinity for the LDL receptors that participate in internalizing the cholesterol in the cell. High levels of apo B might be a good indicator of atherosclerotic heart disease.
Apolipoprotein C (apo C) comprises a large part of VLDL. There are three types of apo C: C1, C2 and C3. Low levels of apo C-2 is associated with hyperlipidemias or accumulation of chylomicrons and triglycerides. Apo C is also involved in cholesterol transportation and cell internalization.
Apolipoprotein ratio, which includes Apolipoprotein A1 and Apolipoprotein B, is used for assessment of the risk for Coronary Heart Disease (CHD), mainly to evaluate the risk of atherogenic heart and peripheral heart diseases. Many individuals with CHD have been found to have normal serum lipids and cholesterol levels while the levels of the apolipoproteins might be elevated. The combined determination of apolipoprotein A-1/apolipoprotein B, and the calculation of the apolipoprotein B : apolipoprotein A-1 ratio can reflect a lipid metabolism disorder and the risk of developing atherosclerosis or coronary heart disease, thus providing an excellent addition to the classical HDL/LDL-cholesterol determination. A high level of apolipoprotein A-1 (HDL) and a low level of apolipoprotein B (LDL) correlate best with a low risk for these diseases.
- Evaluation of cardiovascular and coronary heart disease
- Aid in the diagnosis of suspected hypobetalipoproteinemia
- Evaluation of risk for coronary heart disease and atherosclerosis
- As an aid in diagnosis of abetalipoproteinemia, a-lipoproteinemia, and hypobetalipoproteinemia
- Aid in the diagnosis of abnormal lipid metabolism
- Monitor for lipid therapy
- Secondary testing when LDL levels are increased
Increased in:
- Apo A-1 in pregnancy
- Statin drugs and weight reduction
- Diabetes
- Hemodialysis
- Biliary obstructive disease
- Anorexia nervosa
- Renal failure
- Liver Disease
- Hypothyroidism
- Nephrotic syndrome
- Estrogen administration
- Oral contraceptives
- Weight reduction
Decreased in:
- Coronary artery disease
- Ischemic coronary disease
- Familial hyperalphalipoproteinemia
- Chronic renal failure
- Uncontrolled diabetes
- Smoking
- Inherited hypo-a-lipoproteinemia (e.g. Tangier disease)
- Cholestasis
- Sepsis
- Atherosclerosis
- Hyperthyroidism
- Surgery
- Malnutrition
The ratio of these apoliproteins (A1 to B) when high indicates cardio-protection while a low ratio is indicative of increased risk of heart disease.
Apolipoprotein A1: 100-180 mg/dL
Apolipoprotein B: 48-124 mg/dL
Apolipoprotein B/A1 Ratio:
< 0.25 below risk
0.25-.10 avarage riks
>1.00 above risk
Serum (SST) or Plasma EDTA (Lavender), Heparin (Green)
Stability
- Ambient: 72 hours
- Refrigerated: 10 days
- Frozen: 90 days (Avoid repeated freezing and thawing)
Like all lipid profiles, this panel requires a 12-14 hour fast before blood collection. No food or drink other than water during the 12-14 hours prior to collection.
- Eur Heart J. 2012 May;33(9):1142-9. [PMID: 22507979]
- J Intern Med. 2004 Feb;255(2):188-205. [PMID: 14746556]
- Circulation. 1990 Nov;82(5):1574-94. [PMID: 1977530]
- QJM. 2006 May;99(5):277-87. [PMID: 16504986]
- Adv Exp Med Biol. 1991;285:25-31. [PMID: 1858554]
- Mayo Clin Proc. 1986, 61(5):313-20. [PMID: 3702492]
- Ann N Y Acad Sci. 1985, 454:230-8. [PMID: 3865610]
- Clin Chem. 1989 Jul;35(7):1357-61. [PMID: 2503261]
- Scand J Clin Lab Invest Suppl. 1990;198:58-65. [PMID: 2111937]
- Atherosclerosis. 1971, 13(2):141-6. [PMID: 5560875]
- Atherosclerosis. 1980, 37(1):69-76. [PMID: 7426089]
- N Engl J Med. 1983, 309(7):385-9. [PMID: 6410239]
- Alan Wu. Tietz Clinical Guide to Laboratory Tests, Fourth Edition. Saunders; 4 edition (June 13, 2006). ISBN-10: 0721679757